Metrion Biosciences Ltd, the specialist ion channel contract research and drug discovery company, announced the appointment of Dr Steve Jenkinson as Vice President, Drug Discovery and Safety Assessment.
Oxurion NV announced that it has randomized the last patient in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema .
En la era digital, las redes sociales se han convertido en una parte integral de nuestras vidas, brindándonos conexiones instantáneas y acceso ilimitado a información. Sin embargo, en medio de los beneficios evidentes, también debemos reconocer los peligros asociados con …
Los desiertos, con su vasta extensión y clima árido, son algunos de los ecosistemas más fascinantes de nuestro planeta. Entre ellos, se encuentran aquellos desiertos que se destacan por ser los más secos del mundo, donde la escasez de agua y las condiciones extremas crean …
En este Short advertimos sobre los posibles riesgos de la Inteligencia Artificial. …
Futura Medical plc announces that the US Food and Drug Administration has granted over the counter sale Marketing Authorisation for MED3000, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction as a De Novo Medical Device.
Indivior PLC announces that the U.S. Securities & Exchange Commission declared its registration statement on Form 20-F effective on June 9.
Data of InnoCare’s robust pipelines were presented at the European Hematology Association 2023 Hybrid Congress.
Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic diseases, announced a CNY 180 million Series B financing.
Innovent Biologics, Inc. announced that Phase 1 clinical data of the globally first anti-CD47/PD-L1 bispecific antibody IBI322 for the treatment of anti-PD-1-resistant patients with classic Hodgkin lymphoma was presented in oral presentation at the 28th Annual Meeting of the European Society of Hematology.
